BioSpace News Archive

Genetown

Vizgen Launches MERSCOPE® Platform Grant Program

Vizgen today announced the launch of its MERSCOPE ® Platform Grant Program, open to researchers in Europe and North America.

May 16, 2023
·
3 min read
IRLAB Therapeutics and the McQuade Center for Strategic Research and Development Enter into Agreement to Evaluate IRLAB’s Neuropsychiatric Programs IRL757 and IRL942

IRLAB Therapeutics AB announced the signing of an agreement, with the McQuade Center for Strategic Research and Development, LLC, for MSRD to evaluate the neuropsychiatric compounds IRL757 and IRL942 under exclusivity.

May 16, 2023
·
5 min read
Bio NC

New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

G1 Therapeutics, Inc., a commercial-stage oncology company, described recently presented real-world data that confirm a consistent risk of myelosuppressive events across patients with small cell lung cancer being treated with chemotherapy.

May 16, 2023
·
6 min read
FDA

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Phio Pharmaceuticals Corp. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to proceed with a clinical trial of Phio’s lead product candidate, PH-762.

May 16, 2023
·
4 min read
Covalon, Leader in Compassionate Pediatric Infection Prevention Solutions, to Participate in Neonatal/Fetal Conference in Columbus, Ohio on May 17 - 19, 2023

Covalon Technologies Ltd. today announced it is a silver sponsor of the 2023 Neonatal/Fetal Conference: From the Womb and Beyond being held both virtually and in-person in Columbus, Ohio from May 17 to 19, 2023.

May 16, 2023
·
6 min read
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Immutep Limited today announces it has received positive feedback from the US Food and Drug Administration (FDA), regarding the Company’s late-stage clinical development plans for its first-in-class soluble LAG-3 protein and MHC Class II agonist, eftilagimod alpha (“efti”), for the treatment of 1st line non-small cell lung cancer (NSCLC).

May 16, 2023
·
3 min read
Business

Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023

Qualigen Therapeutics, Inc. today announces financial results for the first quarter ending March 31, 2023, and provides a corporate update.

May 16, 2023
·
12 min read
Smith+Nephew helps personalize robotically-enabled surgery with AI-powered planning software and data visualization platform

Smith+Nephew, the global medical technology company, introduces two key products that close the feedback loop for its robotics and digital surgery portfolio – Personalized Planning powered by AI and RI.INSIGHTS Data Visualization Platform.

May 16, 2023
·
6 min read
Drug Development

LYNK’s LNK01001 Achieved Exciting Phase II Results in Rheumatoid Arthritis

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’) announced that the Phase II clinical trial of LNK01001 in the treatment of rheumatoid arthritis (RA) showed statistically significant differences in efficacy compared with placebo in both primary and key secondary efficacy endpoints, and demonstrated good safety and tolerability.

May 16, 2023
·
3 min read
Drug Development

Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. today announced, after review of all available safety data, that it will advance to the second cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD.

May 16, 2023
·
6 min read